Xencor, Inc. (XNCR)
After hours:
| Previous close | 27.40 |
| Open | 27.50 |
| Bid | 26.75 x 1300 |
| Ask | 29.00 x 1100 |
| Day's range | 27.50 - 28.24 |
| 52-week range | 19.35 - 38.20 |
| Volume | |
| Avg. volume | 390,274 |
| Market cap | 1.671B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.21 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 46.13 |
- Business Wire
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
PASADENA, Calif., March 14, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
- Zacks
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Simply Wall St.
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13%
The analysts covering Xencor, Inc. ( NASDAQ:XNCR ) delivered a dose of negativity to shareholders today, by making a...
